Page 11234..1020..»

Category Archives: Human Longevity

CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

Posted: August 6, 2020 at 7:10 pm

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

See original here:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire

Posted in Human Longevity | Comments Off on CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

Your Pension May Be Gambling On Human Life, Profiting From COVID Deaths – Forbes

Posted: at 7:10 pm

Your pension may gambling on highly-controversial life settlement funds which profit when people die ... [+] prematurely from COVID.

Whether you know it or not, your pension may be gambling on highly-speculative life settlement funds which profit when people die prematurely from COVID. Life settlement funds are controversial for a host of obvious and not-so-obvious reasons. These investments in a pension ensuring the retirement security of workers is doubly problematic.

Many public and private pensions are gambling on highly speculative funds that invest in so-called longevity-contingent assets, such as life insurance policies insuring the lives of individuals who are generally at least 70 years old. The insured individual must have a life expectancy ranging from, say, not less than two years to not more than 15 years. A given fund may have exposure to hundreds of lives in the portfolio with an average insured age of over 80 years old.

The sooner the terminally ill and other elderly insured individuals die, the betteras far as your pension is concerned.

With more than 80% of COVID deaths in the United States occurring in people aged 65 and older, this should be the best of times for gambling on these controversial funds which often promise annualized returns ranging from 8-12%. (Actual net returns are likely to be less than half those promised.)

If so, would it comfort you to know your pension was profiting from the misery of others?

Do you know whether your pension invests in life settlements? Have any such investments been clearly disclosed to you? Do the people managing your pension even know?

Believe it or not, they may not.

Today many alternative investment funds provide that they may withhold disclosure of underlying investments from pensions and participants, including stinky stuff like payday loans and life settlements.

Life settlement funds are controversial for a host of obvious and not-so-obvious reasons. Gambling on these highly speculative investments in a pension ensuring the retirement security of workers is doubly problematic.

Many regulators, lawmakers and other governmental authorities, as well as many insurance companies and insurance industry organizations, oppose the selling and buying of longevity-contingent assets. The industry and some of its participants have long been in legal and regulatory hot water. Opponents of the industry argue that these life insurance transactions are contrary to public policy by promoting financial speculation on human life and all-too-often involve elements of fraud and other wrongdoing.

Ask yourself: Why would an elderly, sickly or terminally ill insured person sell his or her life insurance policy? Because he or she needs cash to cover rising medical costs and living expenses? What are the chances the sale of that individuals life insurance policy may have been coerced or induced by fraud? Its no surprise that thoughtful regulators and lawmakers would be highly concerned.

The limited regulatory oversight of these funds is another major red flag. Many funds take the position that whole life settlements do not constitute securities under the federal securities laws and do not register as investment companies under the Investment Company Act of 1940. Compliance with other federal and state securities laws is also a concern. The SEC has long had difficulty reigning in industry abuses since unless securities are involved the agency generally lacks jurisdiction.

Worst of all, since the portfolio investments of these funds do not currently have a readily available market for valuation purposes, the likelihood that portfolio values, as well as investment returns may be inflated by the managers is high. This is particularly troublesome for open-ended investment funds, where new investors may be buying into a fund at an already inflated Net Asset Value (NAV). The life settlement asset class has had a troubled past with respect to inflated NAVs caused by funds underestimating life expectancies.

In other words, fund managers, are so hopeful that the old and sick insureds will die sooner rather than later, they assume the life expectancies will be shorter.

In Europe, a number of open-end funds (so-called sickened death bond funds) have gated, trapping investors. After waiting several years for the funds to liquidate, investors have recovered only pennies on the dollar.

In my opinion, additional regulatory action regarding overvaluations of the portfolios of these funds is almost certainly coming. If so, your pensionyour retirement securitymay be at risk.

In 2016, the Office of the Virgin Islands Inspector Generalissued a scathing report finding that the Virgin Islands General Employees Retirement System had entered into an extremely risky and questionable life settlement investment that jeopardized about $42 million of its investment portfolio. This was done without performing the necessary due diligence and obtaining the necessary expert advice, before exposing the pension fund to this high-risk investment. As a result, GERS has already written-off 20% or $8.4 million of the remaining value. In addition, GERS also granted a $10 million line of credit to the same partnership that is handling the viatical. The majority of the proceeds were to pay past due and near term premiums for the policies.

An advisor to the pension noted, There is uncertainty on the use of viaticals as an investment by a defined benefit plan. Also, The nature of the investment in viaticals, that is an investment seeking profits off death, raises issues of social responsibility.

To be sure, in my opinion, life settlement funds are the antithesis of socially responsible investing.

Should your retirement savings be in longevity-contingent assets supporting speculation on human life which often involve elements of fraud and other wrongdoing? First, find out whether your pension is invested in these funds, then let your voice be heard. Best case scenarioyour pension is profiting from the misery of others. Far more likelyits losing money playing in this nasty sandbox.

For more on how to protect your pension, see my book Who Stole My Pension?

More:
Your Pension May Be Gambling On Human Life, Profiting From COVID Deaths - Forbes

Posted in Human Longevity | Comments Off on Your Pension May Be Gambling On Human Life, Profiting From COVID Deaths – Forbes

NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound – The Motley Fool

Posted: at 7:10 pm

The coronavirus pandemic hit the business pretty hard, but NeoGenomics (NASDAQ:NEO) had been preparing investors for months. Properly setting expectations turned out to be a great move.

Shares of NeoGenomics reached all-time highs shortly after the company announced second-quarter 2020 operating results. The financial metrics weren't pretty, and there's lingering uncertainty about the course of the coronavirus pandemic and its effects on the business, but investors are largely confident in the long-term strategy.

Can the growth stock maintain its expensive valuation?

Image source: Getty Images.

NeoGenomics is an oncology reference lab operating two business segments: clinical services and pharma services. The former collects patient samples from doctors, performs the test(s) selected by customers from a comprehensive menu, and returns the data. The latter helps biopharmaceutical companies to identify biomarkers for drug development, access oncology-specific datasets from pathologists, and develop and validate companion diagnostics.

When first-quarter 2020 operating results were announced, management prepared investors for a sour showing in the second quarter. The coronavirus pandemic was expected to impact clinical trials, which would hurt both business segments. However, NeoGenomics announced it wouldn't furlough employees and would continue investing in the business.

For the second quarter of 2020, total revenue slipped 14% compared to the year-ago period -- a sharp contrast to the double-digit growth investors have grown accustomed to in recent years. Gross profit sank due to lower revenue per test and higher costs, leaving investors with a relatively weak first-half showing for the business.

Metric

First Half 2020

First Half 2019

Change (YoY)

Clinical services

$166.9 million

$175.2 million

(5%)

Pharma services

$26.1 million

$22.1 million

18%

Total revenue

$193.0 million

$197.3 million

(2%)

Gross profit

$74.4 million

$96.1 million

(22%)

Operating income

($24.2 million)

$7.0 million

N/A

Net income

($13.8 million)

($0.4 million)

N/A

Operating cash flow

($5.0 million)

$1.4 million

N/A

Data source: SEC filing. YoY = year over year.

Pharma services revenue was the only bright spot, although the increase was entirely explained by the recent acquisition of assets from Human Longevity.

Despite the tough operating environment, management didn't flinch. On the second-quarter 2020 earnings conference call, CEO Douglas VanOort laid out a six-part business update comprising strategy and investments. Two developments in particular stood out.

NeoGenomics has converted a portion of its lab space to run up to 10,000 SARS-CoV-2 diagnostic tests per day, which could increase in the future. The business has also made a $25 million investment in a liquid biopsy start-up called Inivata. The equity investment gives the oncology reference lab the exclusive option to acquire Inivata.

More important, the investment provides NeoGenomics the option to commercialize the company's InvisionFirst-Lung liquid biopsy test. The diagnostic tests 37 relevant genes to drive care decisions for non-small cell lung cancer (NSCLC), is covered by Medicare and multiple private insurance payers, and is one of only two next-generation sequencing (NGS) tests with specific Medicare coverage.

NeoGenomics ended June with $331 million in cash, which is more than enough to weather a prolonged downturn. Management acknowledged the uncertainty of the coronavirus pandemic, but has already begun to see signs of a rebound.

In April, test volumes were down 30% compared to the year-ago period. By June, test volumes were back in line with the prior-year period, although they were about 15% below pre-pandemic expectations for 2020. Volumes had not recovered to pre-pandemic expectations through July.

But management remains confident in the long-term plan. NeoGenomics is well-positioned for a strong recovery if and when the market permits. The business doesn't need an exceptional recovery -- a "V-shaped" recovery, if you will -- to climb back to profitability or growth. What's more, it could take advantage of the economic effects of the pandemic to acquire smaller peers that might be struggling.

That said, shares of NeoGenomics are certainly expensive. Is that the price to pay for profitable growth in an uncertain world? Perhaps, but investors might be better off waiting for a pullback, as the current valuation (as with many stocks right now) appears unsustainable in the near-term.

Read more:
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound - The Motley Fool

Posted in Human Longevity | Comments Off on NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound – The Motley Fool

In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Genomic Biomarker Market 2020 Key Players Bio Rad, Beckman Coulter, Myriad…

Posted: at 7:10 pm

Report is a detailed study of the Genomic Biomarker market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Genomic Biomarker market is to help making reliable strategic decisions regarding the opportunities in Genomic Biomarker market. It offers business accounts, industry investors, and industry segments with consequential insights enhancing decision making ability.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Request Report from CMR Website:https://cognitivemarketresearch.com/medical-devicesconsumables/genomic-biomarker-market-report

Global and Regional Genomic Biomarker Market Segmentation by Type: Oncology, Cardiology, Neurology, Nephrology

Global Genomic Biomarker Market Segmentation by Applications: Hospitals, Diagnostic and research laboratories

Major Market Players with an in-depth analysis: Bio Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Request Free Sample Copy of Genomic Biomarker Market Research Report@ https://cognitivemarketresearch.com/medical-devicesconsumables/genomic-biomarker-market-report#download_report

The Genomic Biomarker market report offers the current state of the market around the world. The report starts with the market outline and key components of the Genomic Biomarker market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Genomic Biomarker market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Genomic Biomarker business and market elements.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Genomic Biomarker Market Report 2020 (Coronavirus Impact Analysis on Genomic Biomarker Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Genomic Biomarker market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of Genomic Biomarker product has been completely profiled along with their SWOT. Some of the key players include Bio Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the Genomic Biomarker market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Genomic Biomarker North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/medical-devicesconsumables/genomic-biomarker-market-report#download_report

Chapters Define in TOC (Table of Content) of the Report:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, SegmentationOverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: Complete profiling and analysis of ManufacturersChapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expensesChapter 10: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 11: Marketing Strategy Analysis, Distributors/TradersChapter 12: Market Effect Factors AnalysisChapter 13: Market ForecastChapter 14: Genomic Biomarker Research Findings and Conclusion, Appendix, methodology and data source To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/medical-devicesconsumables/genomic-biomarker-market-report#table_of_contents

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2027.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients.

Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/genomic-biomarker-market-report

Read more from the original source:
In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Genomic Biomarker Market 2020 Key Players Bio Rad, Beckman Coulter, Myriad...

Posted in Human Longevity | Comments Off on In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Genomic Biomarker Market 2020 Key Players Bio Rad, Beckman Coulter, Myriad…

How to live longer: Diet shown to burn fat, improve heart health and to boost longevity – Express

Posted: at 7:10 pm

In ones quest to find solutions to help live a long and disease-free life, numerous theories and suggestions have been declared. Intermittent fasting has gained much notoriety over the pastyear,and according to leading healthexperts, this type of eatingcould be the answer to helping you boost your life longevity. How?

A review of past animal and human studies in The New England Journal of Medicine recommend adopting a way of eating known as intermittent fasting which can help reduce blood pressure, aid in weight loss and improve longevity.

Alternating between fasting and eating can help to improve cellular health.

Professor Mark Mattson from John Hopkins University said the way of eating can help to trigger a metabolic switch.

In metabolic switching, cells use up their fuel stores and convert fat to energy this in turns helps fat to switch from fat-storing to fat-saving and has many health benefits.

The way of eating involves daily-time restricted feeding.

This narrows the time of eating to six to eight hours per day which is also known as 5:2 intermittent fasting, in which people limit themselves to one moderate-sized meal two days each week.

Findings on intermittent fasting range in the diets effectiveness, but some studies in animals and humans have linked the practice to longer lives, healthier hearts and improved cognition.

DON'T MISSHigh blood pressure: Studies show adding this drink to your diet will lower your reading[TIPS]Hair loss treatment: A mineral which strengthens hair follicles to stimulate hair growth[TIPS]High blood pressure: Study reveals the best type of breakfast cereal to lower your reading[TIPS]

When finding benefits of the diet, looking at different countries who adopt this way of eating as a norm often helps.

Residents of Okinawa are known for their extreme longevity and low-calorie, nutrient-rich diet.

Their way of eating has been suggested to help contribute to their long-life spans, low number of obesity and reduced risk of diseases.

Professor Mattson says studies have shown that this switch improves blood sugar regulation, increases resistance to stress and suppresses inflammation.

The professor notes that four studies in both animals and people found intermittent fasting also helped to decrease blood pressure, blood lipid levels and resting heart rates.

Preliminary studies suggest that intermittent fasting could benefit brain health too.

A clinical trial at the University of Toronto found that 220 healthy adults who maintained a calorie restricted diet for two years showed signs of improved memory in a battery of cognitive tests.

Professor Mattson added: Patients should be advised that feeling hungry and irritable is common initially and usually passes after two weeks to a month as the body and brain become accustomed to the new habit.

Mattson suggests a gradual acclimation to fasting rather than going cold turkey will help with this.

Mattsonalsohopes this study will give better insight to physicians, who can pass that guidance on to their patients.

For an added benefit, eating a Mediterranean diet during the eating phasecouldnot only boost longevity but improve heart health too.

See the original post:
How to live longer: Diet shown to burn fat, improve heart health and to boost longevity - Express

Posted in Human Longevity | Comments Off on How to live longer: Diet shown to burn fat, improve heart health and to boost longevity – Express

Precision Medicine Software Industry Market Outlook | Development Factors, Latest Opportunities and Forecast 2025 – AlgosOnline

Posted: at 7:10 pm

Precision Medicine Software Industry Market Outlook | Development Factors, Latest Opportunities and Forecast 2025Published: 9 hours ago Author: Sachin PashteCategory: #news

This report on Precision Medicine Software Industry market Added by Market Study Report, LLC, covers valuable insights based on market valuation, market size, revenue forecast, SWOT Analysis and regional outlook of this industry. The research also presents a precise summary of the industrys competitive spectrum, while drawing attention to the growth prospects and expansion plans adopted by key market players.

The research report on Precision Medicine Software Industry market offers a granular analysis on existing market trends, as well as drivers that are slated to catalyze the market growth during the forecast period. It also highlights major market segments, and key manufacturers. Furthermore, the report also comprises of the restraints which may hamper the remuneration over the analysis timeframe. The report throws light on the business overview keeping in mind the effects of COVID-19 pandemic on the industry vertical.

Request a sample Report of Precision Medicine Software Industry Market at:https://www.marketstudyreport.com/request-a-sample/2836053?utm_source=algosonline.com&utm_medium=TS

Summary of the geographical landscape of the Precision Medicine Software Industry market:

Analyzing the competitive landscape of Precision Medicine Software Industry market:

Ask for Discount on Precision Medicine Software Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2836053?utm_source=algosonline.com&utm_medium=TS

Additional features of the Precision Medicine Software Industry market report:

Table of Contents:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-precision-medicine-software-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

2. COVID-19 Outbreak-Global VR Game Engine Software Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-vr-game-engine-software-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Read More Reports On: https://www.marketwatch.com/press-release/aromatic-compounds-market-progressing-at-a-cagr-of-79-during-the-forecast-period-2020-2025-2020-08-04?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More:
Precision Medicine Software Industry Market Outlook | Development Factors, Latest Opportunities and Forecast 2025 - AlgosOnline

Posted in Human Longevity | Comments Off on Precision Medicine Software Industry Market Outlook | Development Factors, Latest Opportunities and Forecast 2025 – AlgosOnline

Common sense and courage will get us through – News-Press Now

Posted: at 7:10 pm

The news earns me a living, but I dont live the news. When not at work I try to limit my news viewing if I want to enjoy living. If I dont restrict my news consumption, my life will be spent in constant fear.

Illegal immigrants are coming to rob and kill us. Muslims will kill us. Russia China and North Korea will kill us. Police will kill us. Blacks will kill us. Whites will kill us. Mexicans will kill us. The coronavirus will kill us.

Im not saying we shouldnt be cautious and safe, especially when it comes to the coronavirus and all the other fears but use common sense.

According to Lewis & Clark College President Barry Glassner, one of the countrys leading sociologists and author of The Culture of Fear as reported in Rolling Stone magazine, Most Americans are living in the safest place at the safest time in human history.

Around the world, household wealth, education and longevity are on the rise while violent crime and extreme poverty are down. Our air is the cleanest its been in more than a decade, and for the most part our water supply is safe.

Because, according to Glassner, We are living in the most fearmongering time in human history. And the main reason for this is that theres a lot of power and money available to individuals and organizations who can perpetuate these fears.

If we are in the safest of times, why are we more fearful than ever?

Glassner offered this answer: For mass media, insurance companies, Big Pharma, advocacy groups and politicians, your fear is worth billions and your fear is easy to manipulate. Were wired to respond to it above everything else.

Andrew Hubermn, a Stanford neurobiology professor who runs a lab studying fear, said, The more we learn about the brain, the more we learn its not something thats supposed to make you happy all the time. Its primary job is to keep us alive, which is why its so easy to flip people into fear all the time.

I know we have to be extra safe with wearing masks and social distancing during this pandemic, but weve been in safety hyper mode for a long while before.

We dont even let our kids venture down the block or stray too far from our sight. When I was a kid, we were allowed to roam wherever we wanted as long as we were home before dark. We ate green apples, had dirt-clod fights, played in tunnels, rode bikes all over town and survived.

When the city had trucks spraying a kerosene mist for mosquitoes in the summer and kids would run and play in the fumes, parents watched calmly from the porch. We survived that too.

We survived all the boogeymen, real or imagined, through common sense and courage.

That common sense and courage are needed today. We are a strong people. We are survivors. We survived the worst times in history and were here to win another battle.

Read this article:
Common sense and courage will get us through - News-Press Now

Posted in Human Longevity | Comments Off on Common sense and courage will get us through – News-Press Now

Microbiome Therapeutics Market: What’s the Future Potential? – Bulletin Line

Posted: at 7:10 pm

Roots Analysis has announced the addition of Microbiome Therapeutics Market, 2015-2030 report to their offering. The report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of products in this area. While the field has garnered the interest of several companies, there are no approved microbiome drugs available in the market yet; Faecal Microbiota Transplant (FMT) is the only commercially available procedure till date. However, the development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories in the foreseen future.

Ishita Nanda, the principal analyst, said, Among other elements, the report also elaborates on new microbiome based diagnostic solutions being developed and the upcoming opportunities in this market for different stakeholders.One of the key objectives outlined for this report was to understand the future potential of the market. This was done by analyzing:

Nanda added, The study provides a detailed market forecast and opportunity analysis for the short-mid term (2015-2022) and long term (2022-2030). Our opinions and insights, presented in this study, were influenced by several discussions conducted with experts in this area. These included senior representatives at Assembly Biosciences, Da Volterra, Metabiomics, MicroBiome Therapeutics and Rebiotix.

The 218 page report includes detailed profiles and an assessment of the microbiome therapeutics programs of many companies including:

Details of some other firms developing microbiome related diagnostics and companion diagnostics have also been captured. Examples include (in alphabetical order) Admera Health, Biocartis, Enterome Bioscience, Human Longevity, Metabiomics, Microbiome Diagnostics, Viomer, Whole Biome.

For additional details, please visithttp://www.rootsanalysis.com/reports/view_document/microbiome-therapeutics-market-2015-2030/117.htmlor email[emailprotected]

About Roots Analysis

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like us to help you with your growing business needs, get in touch at[emailprotected]

Read the original:
Microbiome Therapeutics Market: What's the Future Potential? - Bulletin Line

Posted in Human Longevity | Comments Off on Microbiome Therapeutics Market: What’s the Future Potential? – Bulletin Line

Covid-19 Impact On Cellular Reprogramming Tools Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2026 |…

Posted: at 7:10 pm

Global Cellular Reprogramming Tools Market report offers in-depth insights, revenue details, and other vital information regarding the global Cellular Reprogramming Tools market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. Global Cellular Reprogramming Tools market report has been segmented on the basis of type, application, and region.

SDMR has recently published a report, on Global Cellular Reprogramming Tools Market Insights, Forecast to 2025. The market research report is a brilliant, complete, and much-needed resource for Cellular Reprogramming Tools . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Cellular Reprogramming Tools market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Final Cellular Reprogramming Tools Report will add the analysis of the impact of COVID-19 on this Market.

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.supplydemandmarketresearch.com/home/contact/1377884?ref=Sample-and-Brochure&toccode=SDMRME1377884

Top Key Keyplayers Covered In This Report: Celgene, Cynata, Advanced Cell Technology, BIOTIME, Osiris Therapeutics, Human Longevity, FUJIFILM Holdings, STEMCELL Technologies, Mesoblast, Astellas Pharma, EVOTEC, Japan Tissue Engineering

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

The Global Cellular Reprogramming Tools Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Cellular Reprogramming Tools market, the market size and growth, as well as the major market participants.

Segmentation by Product:

Adult Stem CellsHuman Embryonic Stem CellsInduced Pluripotent Stem CellsOther

Segmentation by Application:

Drug DevelopmentRegenerative MedicineToxicity TestAcademic ResearchOther

Global Cellular Reprogramming Tools Market: Competitive RivalryThe segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising techniques, and global as well as regional sales efforts of Global Cellular Reprogramming Tools Market. Common characteristics are being considered for segmentation such as global market share, common interests, global demand and access control unit supply. Moreover, the report compares the production value and growth rate of the Global Cellular Reprogramming Tools market across different geographies.While segmentation has been provided to list down various facets of the Cellular Reprogramming Tools market, analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. Summarization of various aspects consisted of the report has also been encompassed.

Scope of the Report: The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Cellular Reprogramming Tools Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

Key Questions Answered: What is the size and CAGR of the global Cellular Reprogramming Tools Market? Which are the leading segments of the global Cellular Reprogramming Tools Market? What are the key driving factors of the most profitable regional market? What is the nature of competition in the global Cellular Reprogramming Tools Market? How will the global Home Appliance market advance in the coming years? What are the main strategies adopted in the global Cellular Reprogramming Tools Market?

Grab Best Discount on Cellular Reprogramming Tools Market Research Report [Single User | Multi User | Corporate Users] @ https://www.supplydemandmarketresearch.com/home/contact/1377884?ref=Discount&toccode=SDMRME1377884

Table of ContentsReport Overview: It includes major players of the global Cellular Reprogramming Tools Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Cellular Reprogramming Tools Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Cellular Reprogramming Tools Market are discussed.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Cellular Reprogramming Tools Market by application, it gives a study on the consumption in the global Cellular Reprogramming Tools Market by application.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles: Almost all leading players of the global Cellular Reprogramming Tools Market are profiled in this section. The analysts have provided information about their recent developments in the global Cellular Reprogramming Tools Market, products, revenue, production, business, and company.

Market Forecast by Production: The production and production value forecasts included in this section are for the global Cellular Reprogramming Tools Market as well as for key regional markets.

Market Forecast by Consumption: The consumption and consumption value forecasts included in this section are for the global Cellular Reprogramming Tools Market as well as for key regional markets.

Value Chain and Sales Analysis: It deeply analyzes customers, distributors, sales channels, and value chain of the global Cellular Reprogramming Tools Market.

Key Findings: This section gives a quick look at important findings of the research study.

About SDMR: We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

Contact Us: Mr. Charles Lee302-20 Misssisauga, Valley, Missisauga,L5A 3S1, Toronto, Canada Phone Number: +1-276-477-5910Email- [emailprotected]

Follow this link:
Covid-19 Impact On Cellular Reprogramming Tools Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2026 |...

Posted in Human Longevity | Comments Off on Covid-19 Impact On Cellular Reprogramming Tools Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2026 |…

Precision Medicine Software Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 – Bulletin Line

Posted: at 7:09 pm

The recent report on GlobalPrecision Medicine Software Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 offered by Credible Markets, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Precision Medicine Software Market.

Impact of Covid-19 in Precision Medicine Software Market: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Precision Medicine Software market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Download FREE Sample Copy of Precision Medicine Software Report @https://www.crediblemarkets.com/sample-request/precision-medicine-software-market-12730

Key players in the global Precision Medicine Software market covered in Chapter 4:

Merck & Co., IncTranslational Software, IncTempus Labs, IncIBM Watson GroupAllscriptsAbbott LaboratoriesAstraZeneca plcSOPHiA GENETICS SAQiagenNantHealth, IncPfizer, IncN-of-One, IncGene42, IncLifeOmic Health, LLCSunquest Information Systems IncGlaxoSmithKline plcRoper TechnologiesFoundation Medicine, IncSyapse, Inc2bPrecise LLCFlatiron Health, IncFabric GenomicsPierianDx, IncHuman Longevity, IncSanofi S.AKoninklijke Philips N.V

In Chapter 11 and 13.3, on the basis of types, the Precision Medicine Software market from 2015 to 2026 is primarily split into:

Cloud-basedOn-premise

In Chapter 12 and 13.4, on the basis of applications, the Precision Medicine Software market from 2015 to 2026 covers:

Healthcare ProvidersResearch Centers & Government InstitutesPharmaceutical & Biotechnology CompaniesOthers

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Enquiry before Buying this Report @ https://www.crediblemarkets.com/enquire-request/precision-medicine-software-market-12730

Some Points from Table of Content

Global Precision Medicine Software Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Chapter 1 Report Overview

Chapter 2 Global Market Growth Trends

Chapter 3 Value Chain of Precision Medicine Software Market

Chapter 4 Players Profiles

Chapter 5 Global Precision Medicine Software Market Analysis by Regions

Chapter 6 North America Precision Medicine Software Market Analysis by Countries

Chapter 7 Europe Precision Medicine Software Market Analysis by Countries

Chapter 8 Asia-Pacific Precision Medicine Software Market Analysis by Countries

Chapter 9 Middle East and Africa Precision Medicine Software Market Analysis by Countries

Chapter 10 South America Precision Medicine Software Market Analysis by Countries

Chapter 11 Global Precision Medicine Software Market Segment by Types

Chapter 12 Global Precision Medicine Software Market Segment by Applications

Chapter 13 Precision Medicine Software Market Forecast by Regions (2020-2026)

Chapter 14 Appendix

The research provides answers to the following key questions:

What is the expected growth rate of the Precision Medicine Software market? What will be the market size for the forecast period, 2020 2026?

What are the major driving forces responsible for transforming the trajectory of the industry?

Who are major vendors dominating the Precision Medicine Software industry across different regions? What are their winning strategies to stay ahead in the competition?

What are the market trends business owners can rely upon in the coming years?

What are the threats and challenges expected to restrict the progress of the industry across different countries?

What are the key opportunities that business owners can bank on for the forecast period, 2020 2026?

Grab Maximum Discount on Precision Medicine Software Market Research Report @https://www.crediblemarkets.com/discount-request/precision-medicine-software-market-12730

About Credible Markets

Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Ask for customization @https://www.crediblemarkets.com/custom-research

Read the original:
Precision Medicine Software Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 - Bulletin Line

Posted in Human Longevity | Comments Off on Precision Medicine Software Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 – Bulletin Line

Page 11234..1020..»